News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
MEDBOT-B Continues to Spike 23%+, Marking 7-day Rally; Toumai Expected to Receive Intensive Approvals This Yr
MEDBOT-B (02252.HK) has risen for seven consecutive days. It opened 2.02% lower this morning (24th) but then managed a rebound, reaching an over-three-month high of $15.04. It last...
Reset
Send
The window will close in 5 seconds
MEDBOT-B Continues to Spike 23%+, Marking 7-day Rally; Toumai Expected to Receive Intensive Approvals This Yr
Close
Recommend
12
Positive
19
Negative
5
 
SHORT SELL
 
STOCK INFO

MEDBOT-B (02252.HK)  -0.120 (-0.767%)    Short selling $1.53M; Ratio 3.009%   has risen for seven consecutive days. It opened 2.02% lower this morning (24th) but then managed a rebound, reaching an over-three-month high of $15.04. It last traded at $14.66, up 23.61%, on a turnover of $569 million.

MEDBOT-B announced that according to preliminary internal statistics, the cumulative order volume of the group's laparoscopic, orthopedic and vascular interventional core products has exceeded 100 units in 2024. Among them, global orders of Toumai Laparoscopic Surgical Robot reached 39 units, with commercial installations breaking through 30 units, and nearly 60 cumulative commercial orders globally. Toumai has submitted marketing certification applications in more than 20 countries or regions and is expected to receive intensive approvals in 2025.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-04-17 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.